JP2008500284A5 - - Google Patents

Download PDF

Info

Publication number
JP2008500284A5
JP2008500284A5 JP2007513296A JP2007513296A JP2008500284A5 JP 2008500284 A5 JP2008500284 A5 JP 2008500284A5 JP 2007513296 A JP2007513296 A JP 2007513296A JP 2007513296 A JP2007513296 A JP 2007513296A JP 2008500284 A5 JP2008500284 A5 JP 2008500284A5
Authority
JP
Japan
Prior art keywords
pyridin
urea
tert
phenyl
butylphenoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007513296A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008500284A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/016422 external-priority patent/WO2005113511A1/en
Publication of JP2008500284A publication Critical patent/JP2008500284A/ja
Publication of JP2008500284A5 publication Critical patent/JP2008500284A5/ja
Pending legal-status Critical Current

Links

JP2007513296A 2004-05-12 2005-05-11 血栓症の治療に有用なｐ２ｙ１レセプターのウレアアンタゴニスト Pending JP2008500284A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US57028804P 2004-05-12 2004-05-12
US66581705P 2005-03-28 2005-03-28
PCT/US2005/016422 WO2005113511A1 (en) 2004-05-12 2005-05-11 Urea antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
US11/126,915 US7388021B2 (en) 2004-05-12 2005-05-11 Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions

Publications (2)

Publication Number Publication Date
JP2008500284A JP2008500284A (ja) 2008-01-10
JP2008500284A5 true JP2008500284A5 (https=) 2008-02-21

Family

ID=35456856

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007513296A Pending JP2008500284A (ja) 2004-05-12 2005-05-11 血栓症の治療に有用なｐ２ｙ１レセプターのウレアアンタゴニスト

Country Status (11)

Country Link
US (2) US7388021B2 (https=)
EP (1) EP1751113B1 (https=)
JP (1) JP2008500284A (https=)
KR (1) KR20070032648A (https=)
AT (1) ATE460402T1 (https=)
AU (1) AU2005245389A1 (https=)
DE (1) DE602005019874D1 (https=)
ES (1) ES2340179T3 (https=)
MX (1) MXPA06013022A (https=)
NO (1) NO20065534L (https=)
WO (1) WO2005113511A1 (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2520763A1 (en) 2003-04-03 2004-10-21 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase
US7470712B2 (en) * 2004-01-21 2008-12-30 Bristol-Myers Squibb Company Amino-benzazoles as P2Y1 receptor inhibitors
EP1765311A4 (en) 2004-03-16 2009-04-29 Univ California REDUCTION OF NEPHROPATHY WITH INHIBITORS OF SOLUBLE EPOXY HYDROLASE AND EPOXYEICOSANOIDS
US7550499B2 (en) 2004-05-12 2009-06-23 Bristol-Myers Squibb Company Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
US7662910B2 (en) 2004-10-20 2010-02-16 The Regents Of The University Of California Inhibitors for the soluble epoxide hydrolase
EP1954696B1 (en) * 2005-01-19 2011-02-23 Bristol-Myers Squibb Company 2-phenoxy-n-(1,3,4-thiadizol-2-yl)pyridin-3-amine derivatives and related compounds as p2y1 receptor inhibitors for the treatment of thromboembolic disorders
DE602006020871D1 (de) * 2005-06-27 2011-05-05 Bristol Myers Squibb Co Lineare harnstoffmimetika-antagonisten des p2y1-rezeptors zur behandlung von thromboseleiden
EP1899299B1 (en) * 2005-06-27 2010-10-20 Bristol-Myers Squibb Company C-linked cyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
WO2007002634A1 (en) * 2005-06-27 2007-01-04 Bristol-Myers Squibb Company Carbocycle and heterocycle antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
AR056867A1 (es) 2005-06-27 2007-10-31 Bristol Myers Squibb Co Antagonistas heterociclicos n- enlazados del receptor de p2y1 utiles en el tratamiento de condiciones tromboticas. composiciones farmaceuticas.
AR059826A1 (es) * 2006-03-13 2008-04-30 Univ California Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble
WO2008023235A1 (en) * 2006-08-25 2008-02-28 Pfizer Products Inc. Pyrazole derivatives as anti-platelet and anti-thrombotic agents
US7960569B2 (en) * 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
AR064864A1 (es) * 2007-01-12 2009-04-29 Astrazeneca Ab Compuestos analogos de piridina vii 543 y composicion farmaceutica
UY30868A1 (es) * 2007-01-12 2008-09-02 Astrazeneca Ab Nuevos compuestos de piridina, composiciones farmacéuticas conteniéndolas y aplicaciones.
US20100137277A1 (en) * 2007-01-12 2010-06-03 Astrazeneca Ab Pyridine compounds and their use as p2y12 antagonists
US8053574B2 (en) * 2007-07-18 2011-11-08 Novartis Ag Organic compounds
WO2009035949A2 (en) * 2007-09-13 2009-03-19 Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors
GB0818033D0 (en) 2008-10-02 2008-11-05 Respivert Ltd Novel compound
MY159230A (en) 2008-10-02 2016-12-30 Respivert Ltd P38 map kinase inhibitors
JP5773877B2 (ja) 2008-10-22 2015-09-02 アキュセラ インコーポレイテッド 眼の疾患及び障害を治療する化合物
AU2009318101A1 (en) * 2008-11-21 2010-05-27 Iroko Cardio Llc Method for reducing thrombocytopenia and thrombocytopenia-associated mortality
JP5670912B2 (ja) 2008-12-11 2015-02-18 レスピバート・リミテツド ｐ３８ＭＡＰキナーゼ阻害剤
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
US8377970B2 (en) 2009-10-08 2013-02-19 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel
EP2528604B1 (en) 2010-01-29 2017-11-22 The Regents of the University of California Acyl piperidine inhibitors of soluble epoxide hydrolase
AU2011223790A1 (en) * 2010-03-01 2012-08-30 Myrexis, Inc. Compounds and therapeutic uses thereof
US8912184B1 (en) 2010-03-01 2014-12-16 Alzheimer's Institute Of America, Inc. Therapeutic and diagnostic methods
FR2965262A1 (fr) * 2010-09-24 2012-03-30 Sanofi Aventis Derives de nicotinamide, leur preparation et leur application en therapeutique
CA2877474A1 (en) * 2011-06-20 2012-12-27 Myrexis, Inc. Compounds and therapeutic uses thereof
WO2014022349A1 (en) * 2012-08-01 2014-02-06 Bristol-Myers Squibb Company 7-hydroxy-spiropipiperidine indolinyl antagonists of p2y1 receptor
US9540323B2 (en) * 2012-08-01 2017-01-10 Bristol-Myers Squibb Company 7-hydroxy-indolinyl antagonists of P2Y1 receptor
SG11201506920QA (en) * 2013-03-15 2015-09-29 Bristol Myers Squibb Co Ido inhibitors
GB201705863D0 (en) 2017-04-11 2017-05-24 Univ London Pyridinium salts and uses thereof
KR102335292B1 (ko) * 2017-06-08 2021-12-06 닛뽕소다 가부시키가이샤 기록 재료 및 화합물
US11428416B2 (en) 2017-12-07 2022-08-30 Pitco Frialator, Inc. Fluid sensor and control system
DE102018113646B4 (de) 2018-06-07 2021-06-24 Helmholtz-Zentrum Dresden - Rossendorf E.V. 2-Phenoxypyridin-3-amin-Derivate und deren Verwendung
WO2021222637A1 (en) 2020-04-30 2021-11-04 United States Government As Represented By The Department Of Veterans Affairs Krüppel-like factor 15 (klf15) small molecule agonists in kidney disease
EP4095134A1 (en) 2021-05-25 2022-11-30 UCL Business Ltd Polycyclic compounds for the treatment of neurological indications
EP4094762A1 (en) 2021-05-25 2022-11-30 UCL Business Ltd Treatment of neurological indications

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL254871A (https=) * 1959-08-14
EP0144101B1 (en) * 1983-11-30 1991-02-06 Janssen Pharmaceutica N.V. Bicyclic heterocyclyl containing n-(bicyclic heterocyclyl)-4-piperidinamines
JPS62280847A (ja) 1986-05-30 1987-12-05 Konica Corp 新規なマゼンタカプラ−を含有するハロゲン化銀写真感光材料
CA1317939C (en) * 1987-07-01 1993-05-18 Janssen Pharmaceutica Naamloze Vennootschap ¬(bicyclic heterocyclyl)methyl and -hetero| substituted hexahydro-1h-azepines and pyrrolidines
JPH0339740A (ja) 1989-07-06 1991-02-20 Konica Corp 転写型熱現像カラー感光材料
NZ238863A (en) * 1990-07-19 1993-03-26 Janssen Pharmaceutica Nv Substituted thiazolyl and pyridinyl derivatives
JP3395285B2 (ja) 1993-10-06 2003-04-07 日本製紙株式会社 感熱記録体
US5547966A (en) * 1993-10-07 1996-08-20 Bristol-Myers Squibb Company Aryl urea and related compounds
DE4443641A1 (de) 1994-12-08 1996-06-13 Bayer Ag Substituierte Carbonsäureamide
EP0809492A4 (en) * 1995-02-17 2007-01-24 Smithkline Beecham Corp IL-8 RECEPTOR ANTAGONISTS
US5691364A (en) * 1995-03-10 1997-11-25 Berlex Laboratories, Inc. Benzamidine derivatives and their use as anti-coagulants
ATE251141T1 (de) 1995-03-10 2003-10-15 Berlex Lab Benzamidin-derivate, deren herstellung und deren verwendung als anti-koagulantien
EP0929218A4 (en) 1996-10-30 2001-05-16 Univ North Carolina P2Y RECEPTOR ANTAGONISTS
US6093742A (en) * 1997-06-27 2000-07-25 Vertex Pharmaceuticals, Inc. Inhibitors of p38
SK286213B6 (sk) * 1997-12-22 2008-05-06 Bayer Corporation Substituované heterocyklické močoviny, farmaceutický prípravok ich obsahujúci a ich použitie
US6329395B1 (en) 1998-06-08 2001-12-11 Schering Corporation Neuropeptide Y5 receptor antagonists
ATE290524T1 (de) 1998-10-20 2005-03-15 Takeda Pharmaceutical Aromatische aminderivate, verfahren zu ihrer herstellung und mittel, die diese enthalten
JP2001089412A (ja) 1999-09-22 2001-04-03 Otsuka Pharmaceut Co Ltd ベンゼン誘導体またはその医薬的に許容される塩
WO2001023358A1 (en) 1999-09-27 2001-04-05 Sagami Chemical Research Center Pyrazole derivatives, intermediates for the preparation thereof, processes for the preparation of both and herbicides containing the derivatives as the active ingredient
CA2385972A1 (en) * 1999-10-01 2001-04-12 Haruhisa Ogita Novel diarylamide derivatives and use thereof as medicines
US7087589B2 (en) 2000-01-14 2006-08-08 The United States Of America As Represented By The Department Of Health And Human Services Methanocarba cycloakyl nucleoside analogues
HRP20020599A2 (en) 2000-01-18 2004-08-31 Pfizer Prod Inc Corticotropin releasing factor antagonists
WO2002088090A2 (en) 2001-04-27 2002-11-07 Vertex Pharmaceuticals Incorporated Pyrazole derived kinase inhibitors
WO2003007955A2 (en) 2001-07-20 2003-01-30 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
EP1435948A1 (en) * 2001-08-06 2004-07-14 Pharmacia Italia S.p.A. Aminoisoxazole derivatives active as kinase inhibitors
MXPA04007832A (es) 2002-02-11 2005-09-08 Bayer Pharmaceuticals Corp Aril-ureas con actividad inhibitoria de angiogenesis.
WO2003068229A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
EP1501829B1 (en) * 2002-05-06 2010-11-24 Vertex Pharmaceuticals Incorporated Thiadiazoles or oxadiazoles and their use as inhibitors of jak protein kinase
BR0312023A (pt) * 2002-06-27 2005-03-22 Novo Nordisk As Composto, composto ativador da glicose cinase, método para evitar a hipoglicemia, uso de um composto, e, composição farmacêutica
US7470712B2 (en) 2004-01-21 2008-12-30 Bristol-Myers Squibb Company Amino-benzazoles as P2Y1 receptor inhibitors
US7550499B2 (en) 2004-05-12 2009-06-23 Bristol-Myers Squibb Company Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
EP1954696B1 (en) 2005-01-19 2011-02-23 Bristol-Myers Squibb Company 2-phenoxy-n-(1,3,4-thiadizol-2-yl)pyridin-3-amine derivatives and related compounds as p2y1 receptor inhibitors for the treatment of thromboembolic disorders
WO2007002634A1 (en) 2005-06-27 2007-01-04 Bristol-Myers Squibb Company Carbocycle and heterocycle antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
DE602006020871D1 (de) 2005-06-27 2011-05-05 Bristol Myers Squibb Co Lineare harnstoffmimetika-antagonisten des p2y1-rezeptors zur behandlung von thromboseleiden

Similar Documents

Publication Publication Date Title
JP2008500284A5 (https=)
JP2008502700A5 (https=)
RU2454405C2 (ru) Производные 3-пиридинкарбоксамида и 2-пиразинкарбоксамида в качестве агентов, повышающих уровень лвп-холестерина
RU2374239C2 (ru) Производные арилпиридина
RU2007101073A (ru) Пятичленные гетероциклы, применимые в качестве ингибиторов сериновой протеазы
RU2003129502A (ru) Соединение, фармацевтическая композиция, применение, способ предупреждения или лечения заболеваний
JP2004534035A5 (https=)
JP2009516685A5 (https=)
JP2004527503A5 (https=)
JP2019537603A5 (https=)
JP2004532227A5 (https=)
JP2010501587A5 (https=)
JP2009519967A5 (https=)
RU2017139727A (ru) Гетероциклические ингибиторы erk1 и erk2 и их применение для лечения злокачественного новообразования
US20070276011A1 (en) Plasminogen Activator Inhibitor-1 Inhibitor
HRP20141190T1 (hr) Disupstituirani derivati piridina kao antikancerogena sredstva
CA2449999A1 (en) Compounds and methods for the treatment or prevention of flavivirus infections
JP2013530240A5 (https=)
RU2008118156A (ru) Производное триарилкарбоновой кислоты
RU2001129155A (ru) Соединения с арильными заместителями (варианты), фармацевтическая композиция и способ лечения расстройства, чувствительного к блокаде натриевых каналов у млекопитающего, способ лечения, профилактики различных заболеваний или уменьшения интенсивности гибели или потери нейронов (варианты), способ облегчения или предупреждения эпилептических припадков у животного (варианты), соединение - радиоактивный лиганд для участка связывания в натриевом канале
RU2004122407A (ru) Амидные производные в качестве активаторов gk
RU2008141510A (ru) Новые соединения
RU2006145205A (ru) Терапевтические соединения: пиридин в качестве каркаса
JP2019516737A5 (https=)
JP2004529931A5 (https=)